Market Place
Sourcing Support
All News #Library
Rare Diseases
Solid Biosciences Receives EU Orphan Drug Status For SGT-003
28 Apr 2026 //
GLOBENEWSWIRE
Solid Bio Provide Interim Positive Clinical Update on Ph1/2 Trial
11 Mar 2026 //
GLOBENEWSWIRE
Solid Biosciences Reports Favorable FDA Type C Meeting Outcome
09 Feb 2026 //
GLOBENEWSWIRE
Solid Bio Highlights 2026 Neuromuscular Pipeline For AAV-SLB101
13 Jan 2026 //
GLOBENEWSWIRE
Solid Biosciences Gets FDA Orphan Status For SGT-212 Gene Therapy
12 Jan 2026 //
GLOBENEWSWIRE
U.S. HHS Adds DMD to Recommended Newborn Screening Panel
16 Dec 2025 //
GLOBENEWSWIRE
Solid Biosciences Gets FDA Rare Pediatric Disease Designation
01 Dec 2025 //
GLOBENEWSWIRE
Solid Biosciences Receives UK Innovation Designation For SGT-003
06 Nov 2025 //
GLOBENEWSWIRE
Kinea Bio Gets $1.1m Investment From Jain Foundation
23 Sep 2025 //
BUSINESSWIRE
FDA Fast Tracks Solid Biosciences` SGT-501 Gene Therapy for CPVT
23 Jul 2025 //
GLOBENEWSWIRE
FDA & Health Canada Approve Solid Biosciences` CPVT Gene Therapy
08 Jul 2025 //
GLOBENEWSWIRE
Solid Bio Receives Rare Pediatric Disease Designation from the FDA for DMD
01 Apr 2024 //
GLOBENEWSWIRE
Solid Biosciences Granted FDA Orphan Drug Designation for SGT-003
16 Jan 2024 //
GLOBENEWSWIRE
Two Rare Disease Biotechs Rake in $170 Million in Public Equity Offerings
19 Mar 2021 //
GLOBALGENES
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.